FIELD: chemistry.
SUBSTANCE: invention relates to a novel compound of formula (I) and a pharmaceutically acceptable salt thereof. In the compound of formula (I)
W is selected from a group consisting of: F, Cl, Br, I, CN, C1-C4 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, CF3, CF2H, CFH2, C2-C6 alkynyl, CON(R1)R2; R1 and R2 are hydrogen, C1-C4 alkyl, C3-C7 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkylthio, C3-C10 aryl or C3-C10 arylalkyl; Ar is heteroaryl or aryl, each of which is substituted with 1–4 substituents, independently selected from a group consisting of: (1) halogen, hydroxy, amide, cyano, -COOH, -SO2NH2, oxo, nitro or alkoxycarbonyl; (2) NR1; and (3) groups of formula (Ia)
, (Ia)
where R4 denotes hydrogen, C1-C4 alkyl or oxo; XR3 is CH; or XR3 is O; or X is N, and R3 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C10 aryl or heteroaryl, (C3-C7 cycloalkyl)C1-C4 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C2-C6 alkanoyl, C1-C6 alkoxycarbonyl, C2-C6 alkanoyloxy, mono- and di-(C3-C8 cycloalkyl) amino C0-C4 alkyl, (4–7 membered heterocycle) C0-C4 alkyl, C1-C6 alkylsulfonyl, mono- and di-(C1-C6 alkyl) sulfonamido or mono- and di-(C1-C6 alkyl) aminocarbonyl, each of which is substituted with 0–4 substitutes independently selected from halogen, hydroxy, cyano, amino, -COOH or oxo; R5 and R6 are independently selected from a group consisting of hydrogen, F, Cl, Br, CN, C1-C4 alkyl and C1-C6 alkoxy; and R7, R8 and R9 are independently selected from a group consisting of hydrogen, C1-C4 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C10 aryl or heteroaryl, C1-C6 alkoxy, C1-C6 alkylthio, C2-C6 alkanoyl, C1-C6 alkoxycarbonyl and C2-C6 alkanoyloxy.
EFFECT: compounds can be used for treating proliferative cell disorder mediated by the activity of FGFR1 and KDR kinases, particularly for treating a cell disorder which is a malignant tumour.
10 cl, 3 dwg, 9 tbl, 60 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL COMPOUNDS OF SUBSTITUTED N-(3-FLUOROPROPYL)PYRROLIDINE, METHODS FOR PRODUCTION THEREOF AND THERAPEUTIC APPLICATION THEREOF | 2017 |
|
RU2742278C2 |
| AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | 2019 |
|
RU2801140C2 |
| PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | 2015 |
|
RU2701188C2 |
| PROTEIN KINASE INHIBITORS FOR ENHANCING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | 2019 |
|
RU2822216C2 |
| ANTI-PROLIFERATIVE COMPOUNDS AND THEIR APPLICATIONS | 2019 |
|
RU2811969C2 |
| JAK KINASE-MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF APPLYING THEREOF | 2010 |
|
RU2529019C2 |
| MODULATORS OF ATP-BINDING TRANSPORTERS | 2010 |
|
RU2552353C2 |
| ALKALOID DERIVATIVES BASED ON AMINOESTERS AND COMPOSITIONS OF MEDICATIONS CONTAINING THEM | 2011 |
|
RU2580835C2 |
| HETEROCYCLIC COMPOUNDS AND METHODS OF APPLICATION | 2009 |
|
RU2525116C2 |
| HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | 2010 |
|
RU2615130C2 |
